May 30 (HealthDay News) -- Xyzal (levocetirizine dihydrochloride) has been approved by the U.S. Food and Drug Administration to treat nasal allergies and chronic hives in people 6 and older, drug makers UCB and Sanofi-Aventis said Tuesday.

In clinical testing involving more than 2,000 people, the drug significantly reduced symptoms of sneezing, itchy and runny nose, and itchy eyes, the companies said in statement. And among people with chronic hives, it reduced the severity of itching and the number and size of the raised blotches, called wheals.

Common side effects included fatigue, dry mouth, and nasal inflammation. People with impaired kidney function shouldn't take the drug, the companies warned. And those who take Xyzal should avoid drinking alcohol or operating heavy machinery.